BRR - Straight from the source

PRESENTATION BY MR. NEIL ANDERSON, CHIEF EXECUTIVE OFFICER, CATHRX LIMITED (CXD)

“Quarterly Investor Update, June Quarter 2008”

http://www.brr.com.au/event/49597

WEDNESDAY, AUGUST 20, 2008, 10:45 AM

            CXD    Welcome to the Cathrx Quarterly Investor Update. My name is Neil Anderson and I am the CEO of Cathrx. In this presentation, I would like to describe the

10                    key activities of the company to the April to June 2008 quarter.

                        Firstly, the marketing quarter highlights. We have begun to execute our European market launch activities in preparation for first sales in September. We also successfully exhibited our products at Cardiostim in June and also

15                    held successful discussions with clinicians, our current distributors and potential future distributors. We have also made a key appointment. Mr. Ged Wallace has joined us in the position of President. Ged will be responsible for our worldwide marketing and business development activities with an initial focus on Europe. He previously was the European head of Boston Scientific.

20

                        With respect to regulatory, we received approval by TUV of our electrode sheath cable making facility at Homebush Bay and the lodgement of another submission for a range of additional decapolar electrode sheath configurations.

25

                        In R&D, we have been focusing on the testing of our next product in readiness for their regulatory submission and clinical trialling. We would hope to make our next submissions next quarter. Other future products in the treatment of AF are also progressing well.

30

                        The key anticipated forthcoming events include first sales in September. Sales in this quarter will be quite small but we will grow as we roll out our plan into the next quarter and beyond. We also plan clinical trials for our diagnostic catheters in Australia. These will lead to marketing approval submissions with

35                    the Australian authorities. Clinical trials will also begin with our irrigated therapeutic catheters. Preparations are underway for a regulatory audit in September of our current manufacturing facility at Eveleigh and our new clean room at Homebush Bay.

40                    Other products are planned to be submitted for marketing approval over the next twelve months and they are all anticipated to be approved by the end of 2009. These are important follow on devices to our launched products and included twenty electrode with duodecapolar catheter sheath, additional shaping stylets which include variable deflectable and loop shapes. From the

45                    feedback in our market research, we anticipate that these are products that will make a significant impact once released to the market. The AF products are a focus for our R&D team for the coming year and we anticipate to have them in clinical trials in the first half of 2009.

                        With respect to intellectual property, two more Australian patents were accepted and one Chinese patent granted. A further US provisional patent for another version of the flower catheter for AF was filed taking our patent families up to a total of 39. Another six patents entered the national phase,

5                      some direct from provisionals while others have been through the PCT route.

                        There was also some progress with respect to both local and international trademarks.

10                    With respect to new personnel, we have made a total of twelve appointments in the second quarter of this year. These include two key appointments in the marketing and commercial development side of the business. These are Ged Wallace as president responsible for worldwide marketing activities and Jamie Platt in the role of commercial development manager. Most of our

15                    other appointments were due to our scaling up of the manufacturing with a number of quality engineering, validation engineering, production assembly and a production assistant role filled.

                        In regard to share capital information, we currently have over 42 million

20                    shares issued and approximately 4 million options issued. The percentage breakdown of the type of shareholder we have is shown in the pie chart.

                        On the financials, we had operating expenses of approximately 3.3 million for the quarter which is similar to the previous quarter. On to the financials, we

25                    had operating expenses of approximately 3.3 million for the quarter which is similar to the previous quarter. At the end of the quarter we had approximately $18 million in the bank with over $4 million worth of equipment.

                        Finally, the key message for shareholders for the quarter is that we have

30                    continued to progress our market launch activities in Europe. All departments have made important progress as we prepare for first sales in September, seek regulatory approval for follow on products and continue the development of others and focus on manufacturing quality and reliability. Key appointments have been made and facility upgrades and expansion has continued in

35                    readiness for this exciting next stage for Cathrx. Thank you for listening and I look forward to presenting news on further progress in Cathrx in the next quarter. Thank you.

PRESENTATION CONCLUDED

Contact brr@brr.com.au for more information

DISCLAIMER: Transcripts made available by Boardroomradio.com is a free service whereby the transcripts are created by one or more third party contractors without any involvement or oversight by Boardroomradio.com or the respective company, firm, partnership or individual that is being transcribed.  Boardroomradio.com and its contractors, client companies, firms, partnerships and guest speakers (paid or otherwise) do not invite reliance upon, nor accept responsibility for, the information they provide. Boardroomradio.com makes every effort to provide a high quality service. However, neither Boardroomradio.com, its transcript providers, nor the providers of any other written or oral data made available on the Boardoomradio.com site (and its partner sites) give any guarantees, undertakings or warranties concerning the accuracy, completeness or up-to-date nature of the information provided. Users should confirm information from another source if it is of sufficient importance for them to do so. Boardroomradio.com, its directors and employees do not accept any liability for the results of any actions taken or not taken on the basis of information in this site, or for any negligent misstatements, errors or omissions.